Purchase this article with an account.
A. Navea, C. Desco, E. Palacios, J. Mataix, M. Garcia-Pous; Bevacizumab-Enhanced Photodynamic Therapy in Exudative Age-Related Macular Degeneration: 6 Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1824.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine whether intravitreal bevacizumab improves the efficacy of photodynamic therapy (PDT) with verteporfin in subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Prospective interventional study. 55 patients with AMD were included and treated with combined photodynamic therapy and intravitreal injection of bevacizumab (1.25mg). Patients underwent best-corrected ETDRS visual acuity testing, optical coherence tomography, angiofluoresceingraphy and ophthalmoscopic examination at baseline and follow-up visits at 3 and 6 months. Visual acuity and OCT were performed monthly. Retreatment was made with intravitreal injection of bevacizumab in early reactivations and photodynamic therapy with verteporfin was associated if the reactivation was in the 3rd or 6th month visit
at six months follow-up, 38% of the patients received only one treatment. The mean number of treatments for every patient was 1.5 intravitreal bevacizumab and 1.17 photodynamic therapies. At six month follow-up, 90% of the cases didn’t need more treatment
The combination of PDT and intravitreal bevacizumab may increase the possibility of improving or stabilizing visual acuity in patients with exudative age-related macular degeneration. The mean number of treatment sessions following combination therapy of intravitreal bevacizumab (1.5mg) and PDT appears relatively less compared to PDT or anti-VEGF alone, but further studies are needed to asses the effects of this treatment.
This PDF is available to Subscribers Only